Psychiatric-Mental Health Nurse Practitioner Boards Review

Take the online 150-question practice test after completing the study guide to simulate board conditions, with a 500-minute window, 70% pass target, post-test reviews, and repeat attempts.

Summarizes pharmacogenomic concerns with carbamazepine and HLA-B*1502 for Stevens-Johnson syndrome and surveys PMHNP topics from odd and rad to Tourette syndrome and cultural formulation interview.

An expert review of questions 11-20 for psychiatric-mental health nurse practitioner boards, detailing lab screening (pregnancy, LFTs, thyroid, CBC), lithium monitoring, ADHD non-stimulants, tic management, safety, and prevention.

High-yield practice questions for psychiatric mental health nurse practitioner boards, questions 21–30, cover thyroid interpretation, Depakote safety, antipsychotic risk, and serotonin syndrome scenarios.

Review questions 31–40 cover pharmacology, comorbidity management, teen fluoxetine risks, antisocial factors, schizophrenia MRI findings, amantadine effects, assertive community treatment, and prevention levels.

Navigate board-style psychiatric scenarios covering manic threats, involuntary treatment, Piaget's preoperational stage, reactive attachment disorder, lamotrigine safety, and culturally sensitive care.

Explore reflective practice strategies for professional growth, including journaling, case discussions, research, supervision, continuing education. Apply pharmacotherapy decisions, patient rights, group therapy benefits, recovery model, and PDSA cycles.

A high-yield review of questions 61–70, covering autism spectrum disorder features, delirium, Alzheimer's dementia, cognitive therapy, transition planning, and neurotransmitter roles in ASD.

Explore a focused review of psychiatric disorders and treatments, including factitious disorder, acute stress disorder, image rehearsal therapy, and management approaches for anxiety, ADHD, schizophrenia cognition, depression aftercare, and pandas.

Engage in a rapid review of psychiatry board questions 81–90, covering tardive dyskinesia, metoclopramide, dopamine signaling, anorexia symptoms, apoptosis, mania indicators, dbt, conversion and adjustment disorders.

Engage in a crunch time review of questions 91–100 covering schizophrenia fundamentals, cognitive assessment with the Folstein scale, drug interactions, and dopamine pathways in treatment.

Reinforce PMHNP concepts across questions 111–120, covering hypothyroidism mimicking depression, Depakote toxicity monitoring, antipsychotic choices for weight and sedation, and safety management for lithium, NMS, serotonin syndrome, and MAOI transitions.

Review of key psychiatric nursing concepts from questions 121–130, covering schizophrenia management, assertive community treatment, antipsychotic dosing, cognitive assessment, mood disorders, and disruptive mood dysregulation disorder.

Covers board-review questions 131–140 on frontotemporal dementia (Pick's disease), lead poisoning, grief therapy for children, exposure and person-centered therapies, scaling in solution-focused therapy, and alcohol metabolism differences by gender.

Prioritize airway management in acute psychosis using the abc approach, and apply pharmacologic safety alongside confidentiality principles across ADHD and mood disorders in this board review.

Crunch time review for questions 141-150 of psychiatric-mental health NP boards, covering reflexes, bulimia nervosa, habeas corpus, MS differential, confidentiality, acamprosate, scope of practice, motivational interviewing, and suicide risk.

Pursue the ANC psychiatric mental health nurse practitioner board review with 40 fill-in-the-blank prompts, a 150-question practice test with rationales, 15 video reviews, and bonus document containing 75 interview questions.